Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.

Myles Ingram,Brianna Lauren,Yoanna S Pumpalova,Gulam Abbas Manji,Susan E. Bates,Chin Hur

Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.

2020

Myles Ingram
Brianna Lauren
Yoanna S Pumpalova
Gulam Abbas Manji
Susan E. Bates
Chin Hur

e16793Background: The 2019 NCCN guidelines recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab-paclitaxel (G-nP) for locally advanced and borderline resectable pancreatic ductal ad...

Keywords:

Oncology
Internal medicine
Gemcitabine
Pancreatic cancer
borderline resectable
FOLFIRINOX
Nab-paclitaxel
Pathology
cost effectiveness
locally advanced
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations